Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

2(40.0%)

Phase 2

2(40.0%)

Early Phase 1

1(20.0%)

5Total

Phase 1(2)

Phase 2(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06599619Recruiting

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Role: lead

NCT04688658Phase 1Terminated

Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Role: lead

NCT07223411Recruiting

Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

Role: lead

NCT03743766Phase 2Completed

Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Role: lead

NCT01943422Phase 1Completed

Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma

Role: lead

NCT01568996Early Phase 1Completed

Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions

Role: lead

NCT01042366Phase 2Terminated

Dendritic Cells (DC) Vaccine for Metastatic Melanoma

Role: lead

All 7 trials loaded